the success of ibrutinib in treating mantle cell lymphoma (mcl)
Published 8 years ago • 357 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
2:35
ash 2014: ibrutinib therapy in mantle cell lymphoma (mcl)
-
1:44
triangle: ibrutinib with soc or as a substitute to autologous transplantation in first-line mcl
-
2:42
the role of ibrutinib in dlbcl and the value of next-generation btk inhibitors
-
0:48
real-world results in the uk for ibrutinib at first relapsed for mcl
-
2:23
zilo-301: phase iii study of zilovertamab ibrutinib vs ibrutinib in r/r mcl
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
1:27
acalabrutinib in combination with umbralisib and ublituximab in previously untreated mcl
-
51:27
chris lewis discusses his advanced mantle cell lymphoma (full story)
-
5:56
body in pieces: saving medical collections (ucl)
-
1:43:48
speciality update with hematologists
-
2:11
pirtobrutinib as a bridge to car-t therapy in b-cell malignancies
-
1:56
ibrutinib treatment and its associated risk factors
-
7:56
triangle: ibrutinib with standard treatment or without autohsct in younger patients with mcl
-
1:13
monitoring patients with cll on ibrutinib-based therapies
-
2:29
ibrutinib maintenance in mcl
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
1:45
the role of non-covalent btkis in the era of covalent btkis for b-cell malignancies
-
1:13
rationale for combining ibrutinib with tisa-cel in mcl
-
2:00
ibrutinib in mantle cell lymphoma - an update
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
2:54
the influence of ibrutinib on progression-free survival and complete survival
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm